Science

Diagnostic Hurdles Mount Off Cape Verde as Labs Balance RT-PCR Windows and Serology Limits

Specialized reference laboratories face tight molecular detection windows and serological cross-reactivity risks while testing suspected Andes orthohantavirus samples from the MV Hondius.

HCD

Hantavirus Cruise Desk

Outbreak Tracking Team · October 21, 2026 · 5 min read

Diagnostic Hurdles Mount Off Cape Verde as Labs Balance RT-PCR Windows and Serology Limits

Narrow Molecular Windows Complicate Acute Detection

Clinical diagnostic workflows responding to suspected Andes orthohantavirus aboard the quarantined expedition vessel MV Hondius off Praia, Cape Verde, are contending with rigorous biological limitations. Clinical virologists and reference laboratories supported by international technical agencies report that identifying active infection depends heavily on when patient specimens are drawn relative to symptom onset. Reverse transcription-polymerase chain reaction (RT-PCR) testing remains the definitive standard for detecting Andes virus viral RNA. Yet, viral kinetics in orthohantavirus infections present an exceptionally tight testing window. In documented cases of Andes virus and related New World orthohantaviruses, viremia peaks during the early prodromal phase—typically characterized by non-specific fevers, myalgia, and gastrointestinal distress. Once patients advance into the cardiopulmonary phase, peripheral blood viral loads often decline rapidly, increasing the probability of false-negative RT-PCR results if testing is conducted several days after respiratory decompensation begins. According to technical guidelines maintained by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), whole blood or serum collected during the initial three to five days of illness yields the highest sensitivity for molecular detection. Beyond that threshold, molecular clearance from the vascular compartment necessitates a transition to serological assays or multi-target testing regimens to reach a definitive diagnosis.

Serological Testing and Cross-Reactivity Challenges

For clinical cohorts presenting later in the disease trajectory, enzyme-linked immunosorbent assays (ELISA) measuring immunoglobulin M (IgM) and immunoglobulin G (IgG) provide the primary avenue for confirmation. Andes virus-specific IgM antibodies are generally detectable at or shortly after the onset of severe cardiopulmonary symptoms, frequently persisting for several months. A reactive IgM test or a fourfold rise in IgG antibody titers between acute and convalescent serum samples provides strong laboratory confirmation of an acute orthohantavirus infection. Still, serology presents distinct operational risks in maritime and international transit settings. Cross-reactivity remains an enduring challenge within the family Hantaviridae. Antigens used in generic hantavirus diagnostic panels often show cross-reactivity between different orthohantaviruses, including Old World strains endemic to Eurasia, such as Puumala, Dobrava-Belgrade, and Hantaan viruses. While Andes virus possesses distinctive antigenic determinants in its envelope glycoproteins (Gn and Gc), shared nucleocapsid protein epitopes across the genus can lead to ambiguous diagnostic readings in patients previously exposed to other viral strains or through broad-spectrum screening assays. And, differential diagnosis in patients presenting with fever and thrombocytopenia in the West African maritime corridor requires ruling out endemic febrile illnesses. Clinicians must simultaneously assess for malaria, dengue, leptospirosis, and regional viral hemorrhagic fevers like Lassa virus, which can mimic the early prodromal manifestations of hantavirus infection. Ensuring that diagnostic panels distinguish between true Andes virus reactivity and non-specific serological noise requires high-complexity secondary testing, including neutralization assays.

West African Laboratory Architecture and Regional Logistics

The maritime location of the MV Hondius off Praia highlights persistent infrastructural bottlenecks for high-consequence pathogen diagnostics in the mid-Atlantic and West African regions.Andes virus is classified as a Biosafety Level 3 (BSL-3) or enhanced containment pathogen, requiring strict biosecurity protocols during specimen handling, centrifugation. Viral extraction to mitigate laboratory-acquired infection risks, particularly given the virus's established capability for person-to-person transmission. Cape Verde possesses national laboratory infrastructure capable of routine diagnostic PCR for established respiratory and vector-borne pathogens. But, highly specialized orthohantavirus molecular primers, validated Andes-specific reagents, and high-containment confirmatory capabilities are concentrated in specialized regional reference nodes. As a result, clinical operations off Praia depend on a tiered laboratory architecture coordinated with the Africa Centres for Disease Control and Prevention (Africa CDC) and the WHO Regional Office for Africa. Under regional outbreak response frameworks, preliminary extraction and inactivated-sample PCR can occur via deployable mobile laboratory platforms or accredited domestic facilities.Confirmatory testing, genomic sequencing. Plaque reduction neutralization testing (PRNT)—the benchmark for resolving ambiguous serological cross-reactivity—typically rely on external reference hubs such as the Institut Pasteur de Dakar in Senegal or designated collaborating centers in Europe. Transporting infectious biological substances across international maritime and airspace boundaries introduces logistical friction.The movement of Category A and Category B infectious substances requires specialized hazardous cargo documentation, cold-chain integrity. Adherence to International Civil Aviation Organization (ICAO) and International Maritime Organization (IMO) hazardous transport standards. Delays in sample transit from ship to shore, and Then to regional reference laboratories, risk prolonging turnaround times for critical clinical and quarantine decisions.

Strengthening Confirmatory Workflows

To bridge the diagnostic gap, international health authorities emphasize paired-sample testing protocols. Frontline medical personnel manage suspected cases by gathering simultaneous acute-phase samples for rapid viral RNA extraction alongside serological baselines, followed by mandatory convalescent sampling spaced 10 to 14 days apart. This dual-track strategy ensures that patients who test RT-PCR negative due to delayed presentation can still be confirmed through seroconversion. Regional health agencies continue working to augment local reagent stockpiles in Cape Verde, supplying targeted primer-probe sets calibrated to the South American Andes lineage and standardized positive control materials.As the vessel remains under monitoring, the accuracy and speed of these laboratory conduits remain central to verifying clinical status, managing isolation protocols. Preventing misclassification during critical public health interventions.